{"schema":"sb.node.v1","id":"sb:e/2f0815951377add942fe2c18","kind":"entity","label":{"text":"pfizer","locale":"en"},"identity":{"anchor":"label:en:pfizer","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy f22bd66b225b3901cd1996e08079b5893bdf41be"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":117,"separatePublishers":42,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-06-25","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.205: about 80% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma","fda_decisions"],"activeDays":31,"assertions":{"regulatory-approval":7,"acquisition":5,"utterance":4,"launch-release":2,"election":2,"military-action":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/528f75d3e8e558b96ef35e7b","kind":"observation","label":"24/7 Wall St. · 2026-10-08 · Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not","url":"https://247wallst.com/investing/2026/10/08/pfizers-yield-is-three-times-bigger-johnson-johnsons-dividend-has-something-pfizer-does-not/"},{"id":"sb:o/9379a66d50b9981d3b10ad3e","kind":"observation","label":"The Hindu · 2026-10-07 · Pfizer partners with GITAM to train rural women for pharmaceutical careers","url":"https://www.thehindu.com/news/national/andhra-pradesh/pfizer-partners-with-gitam-to-train-rural-women-for-pharmaceutical-careers/article71556743.ece"},{"id":"sb:o/17768d62367c05949142174a","kind":"observation","label":"STAT News · 2026-10-06 · STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market","url":"https://www.statnews.com/2026/10/05/vaxcyte-pneumococcal-vaccine-study-pfizer-merck/?utm_campaign=rss"},{"id":"sb:o/e34505e144396b2499803089","kind":"observation","label":"24/7 Wall St. · 2026-10-05 · Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside","url":"https://247wallst.com/investing/2026/10/05/pfizers-turnaround-could-be-bigger-than-investors-think-set-for-20-upside/"},{"id":"sb:o/cf22204febf0c98c7dc09fdb","kind":"observation","label":"BioPharma Dive · 2026-10-03 · Pfizer’s eczema drug clears skin in mid-stage trial","url":"https://www.biopharmadive.com/news/pfizer-eczema-drug-clears-skin-in-mid-stage-trial/831905/"},{"id":"sb:o/322c89017e7cf95616e688d5","kind":"observation","label":"Fierce Pharma · 2026-10-03 · Pfizer touts 'dermatology momentum' as it paints fuller picture of Litfulo's vitiligo potential","url":"https://www.fiercepharma.com/pharma/pfizer-funnels-dermatology-momentum-immunology-expansion"},{"id":"sb:o/675b8000a713a79a5553002c","kind":"observation","label":"The Hindu · 2026-10-01 · Pfizer-Sankar Foundation eye camp screens 1,113 patients","url":"https://www.thehindu.com/news/national/andhra-pradesh/pfizer-sankar-foundation-eye-camp-screens-1113-patients/article71533884.ece"},{"id":"sb:o/d84183a07c6201e806698512","kind":"observation","label":"Atlantic Council · 2026-10-01 · Pfizer CEO Albert Bourla on AI and the future of medicine","url":"https://www.atlanticcouncil.org/inflection-points-with-frederick-kempe/pfizer-ceo-albert-bourla-on-ai-and-the-future-of-medicine/"},{"id":"sb:o/47f9377adf3551219723d602","kind":"observation","label":"Endpoints News · 2026-09-22 · Pfizer, Lilly 'most favored nation' deals to give US share of raised foreign prices","url":"https://endpoints.news/pfizer-lilly-most-favored-nation-deals-to-give-us-share-of-raised-foreign-prices/"},{"id":"sb:o/74b1508740d55879627b19da","kind":"observation","label":"MarketBeat News Feed · 2026-09-22 · Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline","url":"https://www.marketbeat.com/instant-alerts/event-pfizer-refocuses-growth-strategy-as-new-products-offset-covid-decline-2026-09-22/"}],"cursor":"c1.eyJpZCI6InNiOmUvMmYwODE1OTUxMzc3YWRkOTQyZmUyYzE4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d68aa9b405adcbb15db3e75e"},{"kind":"relation","label":"co-mentioned with merck (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c8e6eba6de4f70a02bfedd7d"},{"kind":"relation","label":"co-mentioned with astrazeneca (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3af721897a3e1c068922d746"},{"kind":"relation","label":"co-mentioned with eli lilly (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b2223fecb9d7f11e8d11e214"},{"kind":"relation","label":"co-mentioned with amgen (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/15d6877b87c3e94acbb28973"},{"kind":"relation","label":"co-mentioned with studie (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c806ab2ce4b39f8b623f8cc3"},{"kind":"relation","label":"co-mentioned with roche (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1cae11a5876246971489e82f"},{"kind":"relation","label":"co-mentioned with sanofi (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1249a8a416f1a8445b8c5313"},{"kind":"relation","label":"co-mentioned with novartis (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/985a76bc144b6b775ed3563e"},{"kind":"relation","label":"co-mentioned with bristol myers squibb (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/575c6a51af37f204618fedb3"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/2f0815951377add942fe2c18","mcp":"traverse {\"id\":\"sb:e/2f0815951377add942fe2c18\"}","page":"/entity/pfizer/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2f0815951377add942fe2c18\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2f0815951377add942fe2c18\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2f0815951377add942fe2c18\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/2f0815951377add942fe2c18\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}